Scopus Eşleşmesi Bulundu
6
Atıf
23
Cilt
1098-1111
Sayfa
Özet
Refractory angina (RFA) is an unfavourable condition that is characterized with persistent angina due to reversible myocardial ischemia in patients with coronary artery disease that remains uncontrollable despite an optimal combination of pharmacological agents and revascularization. Despite significant advances in revascularization techniques and agents used in pharmacological therapy, there is still a significant population suffering from RFA and the global prevalence is even increasing. Anti- anginal treatment and secondary risk-factor modification are the traditional approaches for this group of patients. Furthermore, now there is still a large number of alternative treatment options. In order to review traditional and alternative treatment strategies in patients with RFA, we searched Pubmed for articles in English using the search terms “pharmacological therapy, refractory angina”, “alternative therapy, refractory angina” between inception to June 2016. We also went through separately for each alternative treatment modality on Pubmed. To identify further articles, we handsearched related citations in review articles and commentaries. We also included data from the European Society of Cardiology (2013), and the Canadian Society of Cardiology/ Canadian Pain Society (2012) guidelines. Data show that besides traditional pharmacological agents, such as nitrates, beta- blockers or calcium channel blockers, novel antiischemic drugs and if symptoms persist, several non- invasive and/ or invasive alternative strategies may be considered. Impact of some pharmacological agents, such as rho- kinase inhibitors, and novel alternative treatment modalities, such as coronary sinus reducers, stem cell therapy, gene and protein therapy, on outcomes are still under investigation.
Web of Science Eşleşmesi Bulundu
5
WoS Atıf
23
Cilt
Review
Belge Türü
Kaynak: CURRENT PHARMACEUTICAL DESIGN
· s. 1098-1111
Anahtar Kelimeler (WoS)
Havuzumuzdaki Atıflar 0
Bu makaleye, sistemimizdeki Scopus veritabanında bulunan 0 makale atıf yapmıştır. Scopus genel atıf sayısı: 6.
Bu makaleye, kendi Scopus havuzumuzdaki başka bir makaleden atıf kaydı bulunmuyor.
Scimago Dergi Bilgisi
Otomatik ISSN Eşleştirmesi
2017 yılı verileri
Current Pharmaceutical Design
Q2
SJR Quartile
0,883
SJR Skoru
190
H-Index
🔓
Açık Erişim
Kategoriler: Drug Discovery (Q2) · Pharmacology (Q2)
Alanlar: Pharmacology, Toxicology and Pharmaceutics
Ülke: United Arab Emirates
· Bentham Science Publishers
Bu bilgiler makale yılına göre Scimago veritabanından ISSN eşleştirmesiyle otomatik getirilmektedir.
Dergi sıralama verileri Scimago'nun ilgili yılı baz alınmaktadır.
Anahtar Kelimeler
WoS |
Bir kelimeye tıklayıp ilgili kaynaktaki yayınları görün.
Makale Bilgileri
Dergi
Current Pharmaceutical Design
ISSN
13816128
Yıl
2017
/ 4. ay
Cilt / Sayı
23
/ 7
Sayfalar
1098 – 1111
Makale Türü
Derleme Makale
Hakemlik
Hakemli
Endeks
SCI
Teşvik Puanı
14,40
· YÖKSİS Akademik Teşvik
Yayın Dili
İngilizce
Kapsam
Uluslararası
Toplam Yazar
4 kişi
Erişim Türü
Elektronik
Alan
Sağlık Bilimleri Temel Alanı-
Kardiyoloji
YÖKSİS Yazar Kaydı
Yazar Adı
KOÇYİĞİT DUYGU,GÜRSES KADRİ MURAT,YALÇIN MUHAMMED ULVİ,TOKGÖZOĞLU SADBERK LALE
YÖKSİS ID
2423604